Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study

Medical and Pediatric Oncology

Volumn 38, Issue 3, 2002, Pages 158-164

  Dagher, Ramzi ^a   Long, Lauren M ^a   Read, Elizabeth J ^b   Leitman, Susan F ^b   Carter, Charles S ^b   Tsokos, Maria ^a   Goletz, Theresa J ^a   Avila, Nilo ^b   Berzofsky, Jay A ^a   Helman, Lee J ^a   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Ewing sarcoma; IL 2; Immunotherapy; Rhabdomyosarcoma; Translocation; Tumor vaccine

Indexed keywords

DIPHENHYDRAMINE; IBUPROFEN; INFLUENZA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PARACETAMOL; RANITIDINE; RECOMBINANT INTERLEUKIN 2; SYNTHETIC PEPTIDE; THYROXINE; TUMOR VACCINE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; DRUG INDUCED DISEASE; EWING SARCOMA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOTHERAPY; LEUKAPHERESIS; MALE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; SCHOOL CHILD; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERLEUKIN-2; MALE; ONCOGENE PROTEINS, FUSION; PILOT PROJECTS; RECURRENCE; RHABDOMYOSARCOMA, ALVEOLAR; SARCOMA, EWING'S; TRANSLOCATION, GENETIC;

EID: 0036179943     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.1303     Document Type: Article

References (20)

1. Chromosomal translocations in Ewing's sarcoma
2. Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma
3. The biochemistry and cell biology of antigen processing and presentation
4. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia
5. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia
6. Cytotoxic T cell responses against the EWS/FLI-1 Ewing's sarcoma fusion protein and the PAX3/FKHR alveolar rhabdomyosarcoma fusion protein
7. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
8. MHC ligands and peptide motifs: First listing
9. Molecular confirmation of Ewing sarcoma
10. Calcium ionophoretreated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells
11. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2
12. Age, thymopoiesis and CD4+ T lymphocyte regeneration after intensive chemotherapy
13. Age-related changes in human blood lymphocyte subpopulations
14. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T cells
15. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
16. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and eliminiation of tumor cells
17. Antigenspecific inhibition of effector T cell function in humans after injection of immature dendritic cells
18. Efficient presentation of soluble antigen by culture human dendritic cells in maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor a
19. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma